11
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Goats naturally devoid of PrP C are resistant to scrapie

      research-article

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Prion diseases are progressive and fatal, neurodegenerative disorders described in humans and animals. According to the “protein-only” hypothesis, the normal host-encoded prion protein (PrP C) is converted into a pathological and infectious form (PrP Sc) in these diseases. Transgenic knockout models have shown that PrP C is a prerequisite for the development of prion disease. In Norwegian dairy goats, a mutation (Ter) in the prion protein gene ( PRNP) effectively blocks PrP C synthesis. We inoculated 12 goats (4 PRNP +/+, 4 PRNP +/Ter, and 4 PRNP Ter/Ter) intracerebrally with goat scrapie prions. The mean incubation time until clinical signs of prion disease was 601 days post-inoculation (dpi) in PRNP +/+ goats and 773 dpi in PRNP +/Ter goats. PrP Sc and vacuolation were similarly distributed in the central nervous system (CNS) of both groups and observed in all brain regions and segments of the spinal cord. Generally, accumulation of PrP Sc was limited in peripheral organs, but all PRNP +/+ goats and 1 of 4 PRNP +/Ter goats were positive in head lymph nodes. The four PRNP Ter/Ter goats remained healthy, without clinical signs of prion disease, and were euthanized 1260 dpi. As expected, no accumulation of PrP Sc was observed in the CNS or peripheral tissues of this group, as assessed by immunohistochemistry, enzyme immunoassay, and real-time quaking-induced conversion. Our study shows for the first time that animals devoid of PrP C due to a natural mutation do not propagate prions and are resistant to scrapie. Clinical onset of disease is delayed in heterozygous goats expressing about 50% of PrP C levels.

          Related collections

          Most cited references45

          • Record: found
          • Abstract: found
          • Article: not found

          Depleting neuronal PrP in prion infection prevents disease and reverses spongiosis.

          The mechanisms involved in prion neurotoxicity are unclear, and therapies preventing accumulation of PrPSc, the disease-associated form of prion protein (PrP), do not significantly prolong survival in mice with central nervous system prion infection. We found that depleting endogenous neuronal PrPc in mice with established neuroinvasive prion infection reversed early spongiform change and prevented neuronal loss and progression to clinical disease. This occurred despite the accumulation of extraneuronal PrPSc to levels seen in terminally ill wild-type animals. Thus, the propagation of nonneuronal PrPSc is not pathogenic, but arresting the continued conversion of PrPc to PrPSc within neurons during scrapie infection prevents prion neurotoxicity.
            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            Prion propagation and toxicity in vivo occur in two distinct mechanistic phases.

            Mammalian prions cause fatal neurodegenerative conditions including Creutzfeldt-Jakob disease in humans and scrapie and bovine spongiform encephalopathy in animals. Prion infections are typically associated with remarkably prolonged but highly consistent incubation periods followed by a rapid clinical phase. The relationship between prion propagation, generation of neurotoxic species and clinical onset has remained obscure. Prion incubation periods in experimental animals are known to vary inversely with expression level of cellular prion protein. Here we demonstrate that prion propagation in brain proceeds via two distinct phases: a clinically silent exponential phase not rate-limited by prion protein concentration which rapidly reaches a maximal prion titre, followed by a distinct switch to a plateau phase. The latter determines time to clinical onset in a manner inversely proportional to prion protein concentration. These findings demonstrate an uncoupling of infectivity and toxicity. We suggest that prions themselves are not neurotoxic but catalyse the formation of such species from PrP(C). Production of neurotoxic species is triggered when prion propagation saturates, leading to a switch from autocatalytic production of infectivity (phase 1) to a toxic (phase 2) pathway.
              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              The cellular prion protein mediates neurotoxic signalling of β-sheet-rich conformers independent of prion replication.

              Formation of aberrant protein conformers is a common pathological denominator of different neurodegenerative disorders, such as Alzheimer's disease or prion diseases. Moreover, increasing evidence indicates that soluble oligomers are associated with early pathological alterations and that oligomeric assemblies of different disease-associated proteins may share common structural features. Previous studies revealed that toxic effects of the scrapie prion protein (PrP(Sc)), a β-sheet-rich isoform of the cellular PrP (PrP(C)), are dependent on neuronal expression of PrP(C). In this study, we demonstrate that PrP(C) has a more general effect in mediating neurotoxic signalling by sensitizing cells to toxic effects of various β-sheet-rich (β) conformers of completely different origins, formed by (i) heterologous PrP, (ii) amyloid β-peptide, (iii) yeast prion proteins or (iv) designed β-peptides. Toxic signalling via PrP(C) requires the intrinsically disordered N-terminal domain (N-PrP) and the GPI anchor of PrP. We found that the N-terminal domain is important for mediating the interaction of PrP(C) with β-conformers. Interestingly, a secreted version of N-PrP associated with β-conformers and antagonized their toxic signalling via PrP(C). Moreover, PrP(C)-mediated toxic signalling could be blocked by an NMDA receptor antagonist or an oligomer-specific antibody. Our study indicates that PrP(C) can mediate toxic signalling of various β-sheet-rich conformers independent of infectious prion propagation, suggesting a pathophysiological role of the prion protein beyond of prion diseases.
                Bookmark

                Author and article information

                Contributors
                oyvind.salvesen@nmbu.no
                arild.espenes@nmbu.no
                malin.reiten@vetinst.no
                tram.thu.vuong@vetinst.no
                giulia.malachin@nmbu.no
                linh.tran@vetinst.no
                o.andreoletti@envt.fr
                ingrid.olsaker@nmbu.no
                sylvie.benestad@vetinst.no
                michael.tranulis@nmbu.no
                cecilie.ersdal@nmbu.no
                Journal
                Vet Res
                Vet. Res
                Veterinary Research
                BioMed Central (London )
                0928-4249
                1297-9716
                10 January 2020
                10 January 2020
                2020
                : 51
                : 1
                Affiliations
                [1 ]ISNI 0000 0004 0607 975X, GRID grid.19477.3c, Department of Production Animal Clinical Sciences, Faculty of Veterinary Medicine, , Norwegian University of Life Sciences, ; Sandnes, Norway
                [2 ]ISNI 0000 0004 0607 975X, GRID grid.19477.3c, Department of Basic Sciences and Aquatic Medicine, Faculty of Veterinary Medicine, , Norwegian University of Life Sciences, ; Oslo, Norway
                [3 ]ISNI 0000 0000 9542 2193, GRID grid.410549.d, Norwegian Veterinary Institute, ; Oslo, Norway
                [4 ]UMR1225, INRA-ENVT, École Nationale Vétérinaire, Toulouse, France
                Author information
                http://orcid.org/0000-0002-5838-4356
                Article
                731
                10.1186/s13567-019-0731-2
                6954626
                31924264
                cdcecfa6-ab4e-4277-ac8d-ca98945433e5
                © The Author(s) 2020

                Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver ( http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

                History
                : 23 October 2019
                : 17 December 2019
                Funding
                Funded by: The Research Council of Norway
                Award ID: 227386/E40
                Award Recipient :
                Categories
                Research Article
                Custom metadata
                © The Author(s) 2020

                Veterinary medicine
                Veterinary medicine

                Comments

                Comment on this article